Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828535) titled 'Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Condition: Acute Myeloid Leukemia (AML)

Intervention: Drug: Liposome Mitoxantrone Drug: Venetoclax

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 30, 2026

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/stud...